When does the dapagliflozin patent expire?
I can’t give an exact “patent expiry date” from the information provided here because patent expiry depends on which specific patent (or patent family) and which country’s filing you mean. Dapagliflozin is covered by multiple patents (for example, for the drug substance, formulations, and specific uses), and different jurisdictions can expire on different schedules.
If you tell me the country (US, UK, EU, Canada, Japan, etc.) and whether you mean the first generic-competition date or the last patent date, I can narrow it to the relevant expiry timeline.
Does expiry differ between the US, EU, and UK?
Yes. Patent expiry dates vary by:
- Country-specific patent grant timelines and term calculations
- Whether there are supplementary protection mechanisms (commonly used in the EU/UK for medicines)
- Different patent families covering different claims
The result is that the earliest date a generic (or biosimilar-style substitute, where relevant) can launch is usually tied to the most restrictive remaining protection in that jurisdiction, not one single worldwide “dapagliflozin expiry” date.
What counts as “expiry” for drug launch—patents or exclusivity?
Drug launch timing can hinge on different legal protections:
- Patent expiry (the legal end of patent-protected claims)
- Market exclusivity or regulatory exclusivity periods (separate from patents)
- Any remaining “evergreening” patents (newer patents covering formulations or additional indications)
So two dates often matter: when the last relevant patent expires, and when the regulatory/marketing exclusivity ends.
How can I check the exact expiry date quickly?
To identify the correct expiry date, you typically need:
- The jurisdiction
- The patent number(s) or marketing authorization holder
- The relevant claim scope (active ingredient vs formulation vs indication)
- The regulatory protection framework (e.g., supplemental protection certificates in some regions)
If you share the country and the brand name you’re using (dapagliflozin is marketed under multiple brand names), I can help map what to look for and which protections usually drive the launch timeline.
If you mean generic availability, what’s the likely timing issue?
Even after the “main” compound patent term ends, launch may still be blocked if:
- Later patents covering formulations or specific dosing remain in force
- Regulatory exclusivity still applies
- Litigation triggers a delayed entry (common in generics when patents are asserted)
That’s why the “patent expiry” date alone can be misleading without knowing the specific patent set and jurisdiction.
Next question to pin down the answer
Which jurisdiction do you mean (US, EU, UK, etc.), and do you want the “last patent expiry” date or the “earliest generic launch” date?